Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F17%3A10362057" target="_blank" >RIV/00216208:11150/17:10362057 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.mdpi.com/1422-0067/18/8/1612" target="_blank" >http://www.mdpi.com/1422-0067/18/8/1612</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ijms18081612" target="_blank" >10.3390/ijms18081612</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril

Popis výsledku v původním jazyce

Lactacystin is a proteasome inhibitor that interferes with several factors involved in heart remodelling. The aim of this study was to investigate whether the chronic administration of lactacystin induces hypertension and heart remodelling and whether these changes can be modified by captopril or melatonin. Lactacystin treatment increased systolic blood pressure and induced fibrosis of the left ventricle. NF-κB expression in the LV was increased in all treated groups in the cytoplasm, however, in neither group in the nucleus. Although melatonin had no effect on SBP, only this indolamine (but not captopril) reduced the concentration of insoluble and total collagen in the LV and stimulated the NO-pathway in the lactacystin group. We conclude that chronic administration of lactacystin represents a novel model of hypertension with collagenous rebuilding of the LV, convenient for testing antihypertensive drugs or agents exerting a cardiovascular benefit beyond blood pressure reduction.

Název v anglickém jazyce

Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril

Popis výsledku anglicky

Lactacystin is a proteasome inhibitor that interferes with several factors involved in heart remodelling. The aim of this study was to investigate whether the chronic administration of lactacystin induces hypertension and heart remodelling and whether these changes can be modified by captopril or melatonin. Lactacystin treatment increased systolic blood pressure and induced fibrosis of the left ventricle. NF-κB expression in the LV was increased in all treated groups in the cytoplasm, however, in neither group in the nucleus. Although melatonin had no effect on SBP, only this indolamine (but not captopril) reduced the concentration of insoluble and total collagen in the LV and stimulated the NO-pathway in the lactacystin group. We conclude that chronic administration of lactacystin represents a novel model of hypertension with collagenous rebuilding of the LV, convenient for testing antihypertensive drugs or agents exerting a cardiovascular benefit beyond blood pressure reduction.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Molecular Sciences

ISSN

1422-0067

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

8

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

15

Strana od-do

—

Kód UT WoS článku

000408897400015

EID výsledku v databázi Scopus

2-s2.0-85026388328